Wednesday, February 18, 2026 1:57:48 AM
When news hits its back to 1.5 Billion shares traded and good bye $1.00
Recent QNCX News
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 04/01/2026 08:30:02 PM
- Quince Therapeutics settles $16.4M debt with $5.5M payment • IH Market News • 03/30/2026 02:26:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/30/2026 12:35:07 PM
- Quince Therapeutics Settles Approximately $16.4 Million of Debt • Business Wire • 03/30/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/20/2026 08:45:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/12/2026 11:06:31 AM
- Quince Therapeutics Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Alternatives • Business Wire • 02/09/2026 09:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/02/2026 09:30:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/29/2026 09:40:03 PM
- Quince Therapeutics Announces Topline Results from Pivotal Phase 3 NEAT Clinical Trial of eDSP in Ataxia-Telangiectasia • Business Wire • 01/29/2026 08:10:00 PM
- Quince Therapeutics Presents Safety Data from Long-Term eDSP Treatment in Children with Ataxia-Telangiectasia at British Paediatric Neurology Association Annual Meeting • Business Wire • 01/28/2026 09:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/24/2026 01:05:44 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/21/2026 11:10:35 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/21/2026 11:05:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/21/2026 10:59:06 PM
- Quince Therapeutics Announces Last Patient Last Visit in Phase 3 NEAT Clinical Trial in Patients with Ataxia-Telangiectasia • Business Wire • 12/15/2025 01:00:00 PM
- Quince Therapeutics Announces Publication of Use of eDSP in Early-Stage Clinical Studies in Pulmonary and Inflammatory Bowel Disorders • Business Wire • 12/10/2025 09:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/08/2025 01:12:05 PM
- Quince Therapeutics to Participate at Investor Events in December 2025 • Business Wire • 11/24/2025 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/12/2025 09:05:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/12/2025 09:05:30 PM
- Quince Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results • Business Wire • 11/12/2025 09:05:00 PM
- Quince Therapeutics Announces Positive iDSMB Review for eDSP in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia • Business Wire • 11/10/2025 09:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/17/2025 08:11:02 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 10/17/2025 08:10:31 PM
